• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期给予抗雌激素药物后,无胸腺小鼠中他莫昔芬刺激的MCF-7肿瘤生长情况的研究。

Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.

作者信息

Gottardis M M, Jordan V C

机构信息

Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.

出版信息

Cancer Res. 1988 Sep 15;48(18):5183-7.

PMID:3409244
Abstract

Long-term tamoxifen (TAM) therapy was examined in athymic mice bearing MCF-7 tumors of different sizes. Six months of TAM treatment caused no increase in tumor size (compared to placebo treatment) for animals treated initially following implantation of tumor pieces (approximately 1 mm3) or for animals with 0.2-cm2 tumors (grown with 1 month of estrogen treatment). Tumors could be regrown with estradiol treatment in animals treated with either therapy and these tumors contained both estrogen and progesterone receptors. However, more tumors could be restimulated with estradiol following pretreatment with TAM than with placebo. A third group of animals had larger tumors (grown with 7 weeks of estrogen treatment to a approximately 0.6-cm2 area) before TAM or placebo treatment. These tumors partially regressed after 4 months of TAM or placebo therapy but began to regrow in both groups until the end of the experiment at 8 months. Tumors that grew in both groups were estrogen receptor positive and when retransplanted into athymic animals could grow with estradiol. However, the tumor that grew during TAM therapy, when retransplanted, could grow successfully only with further TAM treatment. Tumors growing with TAM contained double the estrogen receptor content of the estradiol-stimulated MCF-7 tumors that were not exposed to TAM [390 +/- 37 (SE) fmol/mg protein versus 174 +/- 14 fmol/mg protein]. These results may represent a form of TAM resistance, i.e., TAM dependence that may occur before hormone independence is exhibited.

摘要

在携带不同大小MCF - 7肿瘤的无胸腺小鼠中检测了长期他莫昔芬(TAM)治疗效果。对于在植入肿瘤块(约1立方毫米)后立即接受治疗的动物,以及患有0.2平方厘米肿瘤(经1个月雌激素治疗生长而来)的动物,6个月的TAM治疗(与安慰剂治疗相比)未导致肿瘤大小增加。在用任何一种治疗方法处理的动物中,用雌二醇治疗后肿瘤都可以重新生长,并且这些肿瘤同时含有雌激素和孕激素受体。然而,与安慰剂相比,用TAM预处理后,更多的肿瘤能用雌二醇重新刺激生长。第三组动物在接受TAM或安慰剂治疗前有更大的肿瘤(经7周雌激素治疗生长至约0.6平方厘米大小)。在TAM或安慰剂治疗4个月后,这些肿瘤部分消退,但两组肿瘤在实验结束时的8个月内又开始重新生长。两组中生长的肿瘤都是雌激素受体阳性,当重新移植到无胸腺动物体内时,用雌二醇可以生长。然而,在TAM治疗期间生长的肿瘤,重新移植后,只有在进一步的TAM治疗下才能成功生长。与未接触TAM的雌二醇刺激的MCF - 7肿瘤相比,在TAM治疗下生长的肿瘤所含雌激素受体含量增加了一倍[分别为390±37(SE)fmol/mg蛋白质和174±14 fmol/mg蛋白质]。这些结果可能代表了一种TAM耐药形式,即可能在表现出激素非依赖性之前就出现的TAM依赖性。

相似文献

1
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.长期给予抗雌激素药物后,无胸腺小鼠中他莫昔芬刺激的MCF-7肿瘤生长情况的研究。
Cancer Res. 1988 Sep 15;48(18):5183-7.
2
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Cancer Res. 1988 Feb 15;48(4):812-5.
3
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.生理浓度雌二醇对无胸腺小鼠体内他莫昔芬刺激生长的乳腺肿瘤的抗肿瘤作用。
Clin Cancer Res. 2000 May;6(5):2028-36.
4
Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice.
Breast Cancer Res Treat. 1994;31(1):117-27. doi: 10.1007/BF00689682.
5
Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.用他莫昔芬的非异构化类似物和代谢物研究他莫昔芬刺激乳腺肿瘤生长的机制。
J Natl Cancer Inst. 1993 May 19;85(10):806-12. doi: 10.1093/jnci/85.10.806.
6
Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.低剂量雌激素疗法逆转他莫昔芬耐药性乳腺癌
J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):249-56. doi: 10.1016/j.jsbmb.2004.12.005.
7
Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer.用于研究“激素依赖性”乳腺癌和子宫内膜癌的免疫缺陷动物。
J Steroid Biochem. 1989;34(1-6):169-76. doi: 10.1016/0022-4731(89)90079-4.
8
Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.新型甾体抗雌激素对他莫昔芬刺激的无胸腺小鼠MCF-7肿瘤变体生长的抑制作用。
Cancer Res. 1989 Aug 1;49(15):4090-3.
9
Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.在无胸腺小鼠体内生长的他莫昔芬刺激的乳腺肿瘤中,三苯乙烯类抗雌激素存在交叉耐药性,但 ICI 182,780 不存在交叉耐药性。
Clin Cancer Res. 2000 Dec;6(12):4893-9.
10
Regulation of estrogen receptor and epidermal growth factor receptor by tamoxifen under high and low estrogen environments in MCF-7 cells grown in athymic mice.在无胸腺小鼠体内生长的MCF-7细胞中,他莫昔芬在高雌激素和低雌激素环境下对雌激素受体和表皮生长因子受体的调节作用
Oncol Rep. 2000 Jan-Feb;7(1):135-40. doi: 10.3892/or.7.1.135.

引用本文的文献

1
Host-defence caerin 1.1 and 1.9 peptides suppress glioblastoma U87 and U118 cell proliferation through the modulation of mitochondrial respiration and induce the downregulation of CHI3L1.宿主防御肽 1.1 和 1.9 通过调节线粒体呼吸抑制胶质母细胞瘤 U87 和 U118 细胞增殖,并诱导 CHI3L1 下调。
PLoS One. 2024 Jun 7;19(6):e0304149. doi: 10.1371/journal.pone.0304149. eCollection 2024.
2
Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.雌激素受体 α 突变、截断、异二聚体及治疗方法。
Endocrinology. 2024 Apr 29;165(6). doi: 10.1210/endocr/bqae051.
3
Therapeutic resistance to anti-oestrogen therapy in breast cancer.
乳腺癌对抗雌激素治疗的耐药性。
Nat Rev Cancer. 2023 Oct;23(10):673-685. doi: 10.1038/s41568-023-00604-3. Epub 2023 Jul 27.
4
Clinical Translation: Targeting the Estrogen Receptor.临床转化:靶向雌激素受体。
Adv Exp Med Biol. 2022;1390:297-309. doi: 10.1007/978-3-031-11836-4_17.
5
Estrogen for the Treatment and Prevention of Breast Cancer: A Tale of 2 Karnofsky Lectures.雌激素治疗和预防乳腺癌:卡氏 2 个讲座的故事。
Cancer J. 2022;28(3):163-168. doi: 10.1097/PPO.0000000000000600.
6
Estrogen Receptor Complex to Trigger or Delay Estrogen-Induced Apoptosis in Long-Term Estrogen Deprived Breast Cancer.雌激素受体复合物触发或延迟长期雌激素剥夺的乳腺癌中雌激素诱导的细胞凋亡。
Front Endocrinol (Lausanne). 2022 Mar 10;13:869562. doi: 10.3389/fendo.2022.869562. eCollection 2022.
7
Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.将科学偶然发现转化为乳腺癌研究和治疗的发现:一个博士生和一个 50 年漫游他莫昔芬团队的故事。
Breast Cancer Res Treat. 2021 Nov;190(1):19-38. doi: 10.1007/s10549-021-06356-8. Epub 2021 Aug 16.
8
From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target.从雌激素受体的纯拮抗剂到纯降解剂:针对同一靶点的不断演进的策略。
ACS Omega. 2021 Mar 30;6(14):9334-9343. doi: 10.1021/acsomega.0c06362. eCollection 2021 Apr 13.
9
Next-Generation Endocrine Therapies for Breast Cancer.乳腺癌的新一代内分泌治疗方法
J Clin Oncol. 2021 Apr 20;39(12):1383-1388. doi: 10.1200/JCO.20.03565. Epub 2021 Mar 11.
10
Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer.临床相关雌激素雌三醇和雌激素模拟物 BMI-135 的药理学和分子机制及其在治疗内分泌抵抗型乳腺癌中的应用。
Mol Pharmacol. 2020 Oct;98(4):364-381. doi: 10.1124/molpharm.120.000054. Epub 2020 Aug 12.